MilliporeSigma
  • Home
  • Search Results
  • Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis.

Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis.

Archives of internal medicine (2005-05-25)
Sean M Bagshaw, William A Ghali
ABSTRACT

Contrast-induced nephropathy (CIN) is an important cause of declines in kidney function and is related to greater morbidity, health care costs, and mortality. Adenosine has been proposed to contribute to the pathophysiological process of CIN. We performed a systematic review and meta-analysis of theophylline, an adenosine antagonist, for the prevention of CIN. Studies were identified in all languages by search of MEDLINE (1966 through November 2003), EMBASE (1980 through week 44 [November] of 2003), and the Cochrane Controlled Clinical Trials Register (1996 through November 2003) databases and selected conference proceedings. We searched for randomized controlled trials comparing theophylline vs control in patients receiving radiocontrast media for angiography or computed tomography. Our primary outcome measures were the risk of CIN, the difference in serum creatinine levels between theophylline and control groups at 48 hours and need for dialysis. Nine randomized controlled trials involving 585 patients were identified and included for analysis. Theophylline protocols and definitions of CIN varied across studies. There was evidence of heterogeneity of results across trials (Q = 9.77; P = .08); therefore, pooled values require cautious interpretation. The overall pooled odds ratio (OR) using a conservative random-effects model was 0.40 (95% confidence interval [CI], 0.14 to 1.16; P = .09) indicating a trend toward reduction in the incidence of CIN with theophylline use. The pooled estimate for the difference in 48-hour serum creatinine levels between the theophylline and control groups was -0.17 mg/dL (95% CI, -0.28 to -0.06 mg/dL) (-15.2 micromol/L [95% CI, -24.6 to -5.7 micromol/L]) (P = .002), indicating that theophylline may be protective in CIN. The incidence of CIN requiring dialysis was uncommon and reported in only 1 case. Theophylline may reduce the incidence of CIN with an efficacy that is perhaps comparable to that reported in studies of N-acetylcysteine. However, findings are inconsistent across studies. A large, well-designed trial that incorporates the evaluation of clinically relevant outcomes is required to more adequately assess the role for theophylline in CIN prevention.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Theophylline, anhydrous, ≥99%, powder
Supelco
Theophylline, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Theophylline melting point standard, Pharmaceutical Secondary Standard; Certified Reference Material
Theophylline, European Pharmacopoeia (EP) Reference Standard
USP
Theophylline, certified reference material, United States Pharmacopeia (USP) Reference Standard
Supelco
Theophylline solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®